Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015–2018)

Analysis of GP prescribing data estimates that use of glargine biosimilars generated savings of £900,000 between October 2015 and December 2018, compared to £25.6 million of missed savings during this period (3.42% uptake). Rates of adoption varied widely across CCGs.


Diabetes Care